Generics, Budgeting, And The Stubborn Persistence Of Cost Savings
ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.
You may also be interested in...
Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.
Five-year plan includes multi-phased approach to ALS at the same time that Amylyx’s AMX0035 is pending review with a late September decision deadline; action plan’s mid-term priorities for FY 2023-2024 include a cell and gene therapies safety project.
Committee Chair Maria Cantwell (D-Wash.) solicits advice from witnesses for additional authorities to conduct oversight of PBMs and pushes for a GAO study.